2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Animal Model
PAPER

4112 Cysteine-optimized FLT3 CAR T cell engineering promotes superior anti-leukemia functionality in preclinical models of KMT2A-rearranged acute lymphoblastic leukemia

Shubhmita Bhatnagar, PhD, Michael C Yarnell2, Sarah E. Haines3, Camilo Arenas Merizalde4, Terry Fry, MD5, Sarah Tasian, MD6
1 Children’s Hospital of Philadelphia, Philadlephia, Pennsylvania, United States
2 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
3 Children’s Hospital of Philadelphia, Philadlephia, Pennsylvania, United States
4 Children’s Hospital of Philadelphia, Philadlephia, Pennsylvania, United States
5 Children's Hospital Colorado, Aurora, Colorado, United States, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
6 Children’s Hospital of Philadelphia, Philadlephia, Pennsylvania, United States, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States

Background

Infants, children, and adults with relapsed or chemorefractory KMT2A-rearranged (KMT2A-R) B acute lymphoblastic leukemia (B-ALL) or mixed phenotype acute leukemia (MPAL) continue to experience poor clinical outcomes despite advances in antibody-based and cellular immunotherapies. Although CD19 chimeric antigen receptor (CAR) T cells have transformed the salvage therapy landscape, subsequent relapse occurs in up to 50% of treated patients due to poor CAR T cell persistence, functional exhaustion, and/or CD19 antigen loss/escape, including myeloid lineage drift/switch. Wild-type FLT3 is highly expressed in KMT2A-R ALL and represents an attractive alternative therapeutic target. Although our previously developed NC7-FLT3CAR demonstrated robust preclinical activity in preclinical models of KMT2A-rearranged ALL and an associated lineage switch acute myeloid leukemia (LS-AML), attenuated Th1 cytokine production suggested suboptimal functional fitness (Niswander Haematologica 2023). We thus employed rational CAR engineering strategies to optimize FLT3 antigen-binding domains and receptor architecture with the goal of enhancing in vivo CAR T cell efficacy and long-term persistence.

Methods

Eighteen next-generation FLT3 CAR constructs were generated using complementary engineering strategies. First, the original NC7 scFv was modified by introducing framework-region cysteine substitutions to create disulfide-stabilized variants (dsNC7). In parallel, fully human FLT3-binding scFvs and single-domain variable heavy-chain (VH) antibodies were isolated from a human B-cell phage display library and optimized through affinity maturation. Biepitopic binders were generated by combining scFVs and VHs targeting discrete epitopes of the Flt3 extracellular domain. Candidate binders were then incorporated into second-generation CAR constructs containing CD3ζ signaling domains with either CD28 or 4-1BB costimulatory domains.

Lead constructs were selected following functional in vitro screening against FLT3+ B-ALL and AML cell lines. Anti-leukemia efficacy was subsequently evaluated in multiple patient-derived xenograft (PDX) models of infant, pediatric/adolescent, and adult KMT2A-R ALL with paired LS-AML for some models occurring in the patients following CD19CART therapy. Engrafted PDX mice (n=5-10/cohort) were randomized to treatment with saline, mock-transduced T cells, original NC7-FLT3CART, or one of four best-in-class optimized FLT3CARTs (dsNC7, dsNC7-F7, F7-dsNC7, VH2G5F7). Leukemia burden and CAR T-cell expansion were monitored serially by flow cytometric analysis of peripheral blood and confirmed in spleen/bone marrow at study endpoints. Cytokine production was assessed to compare functional activation between constructs.

Results

Engineering modifications substantially enhanced FLT3CART functionality. Cysteine disulfide stabilization of the original NC7 scFv improved inflammatory cytokine production while preserving antigen recognition and resulted in greater in vivoanti-leukemia activity compared to that of the original NC7-FLT3CART. Screening of newly identified fully human FLT3 binders further identified several candidates with robust functional activity. Affinity-enhanced VH variants generated via targeted CDR3 sequence optimization demonstrated improved type 1 cytokine responses and robust inhibition of in vivoleukemia proliferation in cell line and PDX models.

Across multiple KMT2A-R ALL and LS-AML PDX models, disulfide-optimized or affinity-enhanced VH FLT3CARTs consistently demonstrated superior leukemia control relative to NC7-FLT3CART with best in vitro and in vivo activity achieved by the dsNC7-FLT3CART product. Enhanced CAR T cell expansion in vivo was accompanied by increased IFN-γ production, suggesting improved activation and persistence with a manageable toxicity profile in preclinical models.

Conclusions

Structure-guided optimization of FLT3CARTs significantly enhanced effector function, in vivo expansion, and anti-leukemia activity relative to our original NC7-FLT3CART platform in preclinical KMT2A-rearranged B-ALL models. Comprehensive evaluation across additional KMT2A-R ALL and LS-AML PDX models is ongoing to define further and to validate construct-specific activity, persistence, and functional durability with the goal of nominating a lead FLT3 CAR construct candidate for planned first-in-human phase 1 clinical trial evaluation in adults and children with relapsed/refractory FLT3+ AML or KMT2A-R ALL/MPAL.
Shubhmita Bhatnagar, PhD: No relevant conflicts of interest to declare.